Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.

Recombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like sympt...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilleece, M. H., Scarffe, J. H., Ghosh, A., Heyworth, C. M., Bonnem, E., Testa, N., Stern, P., Dexter, T. M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977892/
https://www.ncbi.nlm.nih.gov/pubmed/1637669
_version_ 1782135359940853760
author Gilleece, M. H.
Scarffe, J. H.
Ghosh, A.
Heyworth, C. M.
Bonnem, E.
Testa, N.
Stern, P.
Dexter, T. M.
author_facet Gilleece, M. H.
Scarffe, J. H.
Ghosh, A.
Heyworth, C. M.
Bonnem, E.
Testa, N.
Stern, P.
Dexter, T. M.
author_sort Gilleece, M. H.
collection PubMed
description Recombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like symptoms and elevated liver enzymes. Modest but significant elevations of neutrophil and platelet counts occurred. No clear evidence of antitumour effects emerged although pain in metastatic lymph nodes and a small fall in myeloma paraprotein levels during dosing were observed. In vitro and murine in vivo studies indicate that patients with lymphoproliferative disease should be selected for Phase II trials.
format Text
id pubmed-1977892
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19778922009-09-10 Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial. Gilleece, M. H. Scarffe, J. H. Ghosh, A. Heyworth, C. M. Bonnem, E. Testa, N. Stern, P. Dexter, T. M. Br J Cancer Research Article Recombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like symptoms and elevated liver enzymes. Modest but significant elevations of neutrophil and platelet counts occurred. No clear evidence of antitumour effects emerged although pain in metastatic lymph nodes and a small fall in myeloma paraprotein levels during dosing were observed. In vitro and murine in vivo studies indicate that patients with lymphoproliferative disease should be selected for Phase II trials. Nature Publishing Group 1992-07 /pmc/articles/PMC1977892/ /pubmed/1637669 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Gilleece, M. H.
Scarffe, J. H.
Ghosh, A.
Heyworth, C. M.
Bonnem, E.
Testa, N.
Stern, P.
Dexter, T. M.
Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
title Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
title_full Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
title_fullStr Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
title_full_unstemmed Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
title_short Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
title_sort recombinant human interleukin 4 (il-4) given as daily subcutaneous injections--a phase i dose toxicity trial.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977892/
https://www.ncbi.nlm.nih.gov/pubmed/1637669
work_keys_str_mv AT gilleecemh recombinanthumaninterleukin4il4givenasdailysubcutaneousinjectionsaphaseidosetoxicitytrial
AT scarffejh recombinanthumaninterleukin4il4givenasdailysubcutaneousinjectionsaphaseidosetoxicitytrial
AT ghosha recombinanthumaninterleukin4il4givenasdailysubcutaneousinjectionsaphaseidosetoxicitytrial
AT heyworthcm recombinanthumaninterleukin4il4givenasdailysubcutaneousinjectionsaphaseidosetoxicitytrial
AT bonneme recombinanthumaninterleukin4il4givenasdailysubcutaneousinjectionsaphaseidosetoxicitytrial
AT testan recombinanthumaninterleukin4il4givenasdailysubcutaneousinjectionsaphaseidosetoxicitytrial
AT sternp recombinanthumaninterleukin4il4givenasdailysubcutaneousinjectionsaphaseidosetoxicitytrial
AT dextertm recombinanthumaninterleukin4il4givenasdailysubcutaneousinjectionsaphaseidosetoxicitytrial

Ejemplares similares